A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).

NCT Number	NCT06506916
Lead Sponsor	UCB Biopharma SRL
Conditions	Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Enrollment	89 participants
Start Date	2024-07-29
Primary Completion	2027-03-09 (estimated)
Study Completion	2028-03-14 (estimated)
Updated on ClinicalTrials.gov	2026-07-17